Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 4/20 | 0.50 |
| ▸ | AKR1A1 | P14550 | 2/20 | 0.50 |
| ▸ | BACE1 | P56817 | 7/20 | 0.41 |
| ▸ | CTSD | P07339 | 4/20 | 0.39 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.39 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1173343 | 1.00 | AKR1B1 (0.50) | AKR1B1AKR1A1BACE1CTSDBACE2 | |
| SCHEMBL15535569 | 0.77 | AKR1B1 (0.49) | AKR1B1AKR1A1PTGER3 | |
| SCHEMBL15535570 | 0.77 | AKR1B1 (0.49) | AKR1B1AKR1A1PTGER3 | |
| SCHEMBL542616 | 0.75 | LMNA (0.51) | AKR1B1AKR1A1BACE1PTGER3LMNA | |
| SCHEMBL20135344 | 0.73 | AKR1B1 (0.44) | AKR1B1AKR1A1PTGER3LMNA | |
| SCHEMBL29688609 | 0.73 | AKR1B1 (0.44) | AKR1B1AKR1A1PTGER3LMNA | |
| SCHEMBL204119 | 0.73 | LMNA (0.51) | AKR1B1LMNA | |
| SCHEMBL4385865 | 0.73 | LMNA (0.51) | AKR1B1LMNA | |
| SCHEMBL6135313 | 0.73 | LMNA (0.51) | AKR1B1LMNA | |
| SCHEMBL14856024 | 0.73 | BACE1 (0.40) | AKR1B1AKR1A1BACE1CTSDBACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2855469-B1 | 5-AMINO[1,4]THIAZINES AS BACE 1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-06-19 | — | — | EP | disclosed |
| EP-3083644-B1 | 5-ARYL-1-IMINO-1-OXO-[1,2,4]THIADIAZINES | HOFFMANN LA ROCHE (CH) | 2019-03-13 | — | — | EP | disclosed |
| US-9605006-B2 | 5-aryl-1-imino-1-oxo-[1,2,4]thiadiazines | HOFFMANN-LA ROCHE INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20160318952-A1 | 5-ARYL-1-IMINO-1-OXO-[1,2,4]THIADIAZINES | HOFFMANN-LA ROCHE INC. (US) | 2016-11-03 | — | — | US | disclosed |
| EP-3083644-A1 | 5-ARYL-1-IMINO-1-OXO-[1,2,4]THIADIAZINES | F. Hoffmann-La Roche AG (CH) | 2016-10-26 | — | — | EP | disclosed |
| US-9273042-B2 | 5-amino[1,4]thiazines as BACE 1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9242943-B2 | 1,4 oxazines as BACE1 and/or BACE2 inhibitors | SIENA BIOTECH S.P.A. (IT) | 2016-01-26 | — | — | US | disclosed |
| WO-2015091595-A1 | 5-ARYL-1-IMINO-1-OXO-[1,2,4]THIADIAZINES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-06-25 | — | — | WO | disclosed |
| US-20150141413-A1 | 5-AMINO[1,4]THIAZINES AS BACE 1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-05-21 | — | — | US | disclosed |
| EP-2855469-A1 | 5-AMINO[1,4]THIAZINES AS BACE 1 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2015-04-08 | — | — | EP | disclosed |
| EP-2665713-A1 | 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-11-27 | — | — | EP | disclosed |
| CN-103328454-A | 1,4 oxazines as BACE1 and/or BACE2 inhibitors | HOFFMANN LA ROCHE | 2013-09-25 | — | — | CN | disclosed |
| US-20130196984-A1 | 3-AMINO-5-PHENYL-56-DIHYDRO-2H-[1,4]OXAZINES | SIENA BIOTECH S.P.A. (IT) | 2013-08-01 | — | — | US | disclosed |
| US-8399459-B2 | 1,4 oxazines as BACE1 and/or BACE2 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120214806-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINES | ANDREINI MATTEO (IT) | 2012-08-23 | — | — | US | disclosed |
| US-20120196863-A1 | 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | SIENA BIOTECH S.P.A. (IT) | 2012-08-02 | — | — | US | disclosed |
| WO-2012098064-A1 | 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| US-20120184540-A1 | 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-19 | — | — | US | disclosed |
| US-8188079-B2 | 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110046122-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINES | SIENA BIOTECH S.P.A. (IT) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318952-A1 | 5-ARYL-1-IMINO-1-OXO-[1,2,4]THIADIAZINES | BACE1, BACE2, PSEN1 | AKR1B1 568/4885AKR1A1 650/4885BACE1 1/4885 |
| US-20120184540-A1 | 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | BACE2, BACE1, PSEN1 | AKR1B1 405/4885AKR1A1 535/4885BACE1 2/4885 |
| US-20130196984-A1 | 3-AMINO-5-PHENYL-56-DIHYDRO-2H-[1,4]OXAZINES | BACE2, BACE1, APP | AKR1B1 542/4885AKR1A1 743/4885BACE1 2/4885 |
| US-20120196863-A1 | 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | BACE2, BACE1, PSEN1 | AKR1B1 379/4885AKR1A1 508/4885BACE1 2/4885 |
| US-20120214806-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINES | BACE2, BACE1, APP | AKR1B1 673/4885AKR1A1 788/4885BACE1 2/4885 |
| US-20110046122-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINES | BACE2, BACE1, APP | AKR1B1 673/4885AKR1A1 788/4885BACE1 2/4885 |
| US-20150141413-A1 | 5-AMINO[1,4]THIAZINES AS BACE 1 INHIBITORS | BACE1, BACE2, PSEN1 | AKR1B1 662/4885AKR1A1 610/4885BACE1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.